Quantitative [F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.

Sorace AG, Syed AK, Barnes SL, Quarles CC, Sanchez V, Kang H, Yankeelov TE
Mol Imaging Biol. 2017 19 (1): 130-137

PMID: 27506906 · PMCID: PMC5214951 · DOI:10.1007/s11307-016-0994-1

PURPOSE - Evaluation of [F]fluoromisonidazole ([F]FMISO)-positron emission tomography (PET) imaging as a metric for evaluating early response to trastuzumab therapy with histological validation in a murine model of HER2+ breast cancer.

PROCEDURES - Mice with BT474, HER2+ tumors, were imaged with [F]FMISO-PET during trastuzumab therapy. Pimonidazole staining was used to confirm hypoxia from imaging.

RESULTS - [F]FMISO-PET indicated significant decreases in hypoxia beginning on day 3 (P < 0.01) prior to changes in tumor size. These results were confirmed with pimonidazole staining on day 7 (P < 0.01); additionally, there was a significant positive linear correlation between histology and PET imaging (r  = 0.85).

CONCLUSIONS - [F]FMISO-PET is a clinically relevant modality which provides the opportunity to (1) predict response to HER2+ therapy before changes in tumor size and (2) identify decreases in hypoxia which has the potential to guide subsequent therapy.

MeSH Terms (14)

Animals Biomarkers, Tumor Cell Line, Tumor Disease Models, Animal Female Fluorescent Antibody Technique Mammary Neoplasms, Animal Misonidazole Nitroimidazoles Positron-Emission Tomography Receptor, ErbB-2 Trastuzumab Tumor Burden Tumor Hypoxia

Connections (1)

This publication is referenced by other Labnodes entities: